Join our daily newsletter At The Bell to receive exclusive market insights
- Noxopharm (NOX) has been cleared to up the dosage of its COVID-19 Veyonda treatment and progress to the final stages of the dose-escalation study
- An independent committee voted unanimously to move patient doses of Veyonda — which was primarily a cancer treatment — from 800 and 1200 milligrams to 1800 milligrams
- Noxopharm CEO says although still in early days, the progress of the trial offers a boost in confidence for Veyonda as a treatment for respiratory conditions
- It marks the fifth and final stage of the first half of the two-part study, with the dose-expansion expected next
- Noxopharm shares are up a healthy 3.85 per cent following the announcement, trading at 54 cents each
Noxopharm (NOX) has been cleared to up the dosage of its COVID-19 Veyonda treatment and progress to the final stages of the dose escalation study.
The approval was given by the Safety Steering Committee, with independent investigators voting “unanimously” to move from 800 and 1200 milligrams Veyonda doses to 1800 milligrams.
Veyonda was primarily used as a cancer treatment drug.
Upped doses of Veyonda will now be administered to the fifth and final cohort of patients in the NOXCOVID study, which aims to validate Veyonda as a potential aiding treatment for respiratory infections associated with COVID-19.
Comprised of two-parts, the first half of the study covers dose escalation, where five cohorts of patients with COVID-19 related respiratory ailments are given daily doses of Veyonda.
Dosages are increased and progressed incrementally— 400, 600, 800, 1200 and 1800 milligrams — once the safety profile for each has been reviewed.
The second stage of NOXICOVID is the dose-expansion phase, which will use the dose determined to be optimal to focus on safety and meet biomarker and clinical endpoints.
Noxopharm Chief Executive Officer Dr Graham Kelly says although still in early days, the progress of the trial offers a boost in confidence for Veyonda as a treatment for respiratory conditions.
“The progress of the trial is serving to boost our confidence that Veyonda
is capable of meeting its primary objective of blocking the cytokine release syndrome causing that rapid deterioration, and doing so in a well-tolerated and minimally-intrusive way,” he explained.
Noxopharm shares are up a healthy 3.85 per cent following the announcement, trading at 54 cents each at 2:23 pm AEDT.
